Qlife Holding AB (publ) (QLIFE.ST)
SEK 2.08
(2.46%)
SEK 2.08
(2.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 20.73 Million SEK | -60.47% |
| 2022 | 52.44 Million SEK | 1316.56% |
| 2021 | 3.7 Million SEK | -6.47% |
| 2020 | 3.95 Million SEK | -5.54% |
| 2019 | 4.19 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 9.26 Million SEK | -55.33% |
| 2024 Q2 | 7.96 Million SEK | -14.04% |
| 2023 Q4 | 20.73 Million SEK | 84.67% |
| 2023 Q2 | 7.54 Million SEK | -87.46% |
| 2023 FY | 20.73 Million SEK | -60.47% |
| 2023 Q1 | 60.11 Million SEK | 14.63% |
| 2023 Q3 | 11.22 Million SEK | 48.87% |
| 2022 Q1 | 4.46 Million SEK | 20.64% |
| 2022 FY | 52.44 Million SEK | 1316.56% |
| 2022 Q2 | 58.24 Million SEK | 1204.23% |
| 2022 Q3 | 70.27 Million SEK | 20.65% |
| 2022 Q4 | 52.44 Million SEK | -25.38% |
| 2021 FY | 3.7 Million SEK | -6.47% |
| 2021 Q1 | 19.71 Million SEK | 398.13% |
| 2021 Q3 | 3.69 Million SEK | -11.59% |
| 2021 Q4 | 3.7 Million SEK | 0.24% |
| 2021 Q2 | 4.17 Million SEK | -78.81% |
| 2020 Q1 | 4.45 Million SEK | 6.24% |
| 2020 Q2 | 4.21 Million SEK | -5.23% |
| 2020 FY | 3.95 Million SEK | -5.54% |
| 2020 Q4 | 3.95 Million SEK | -6.8% |
| 2020 Q3 | 4.24 Million SEK | 0.66% |
| 2019 FY | 4.19 Million SEK | 0.0% |
| 2019 Q4 | 4.19 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 98.715% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 98.715% |
| Arcoma AB | 3.87 Million SEK | -435.27% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 91.106% |
| BICO Group AB (publ) | 1.85 Billion SEK | 98.881% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 87.519% |
| CellaVision AB (publ) | 64.7 Million SEK | 67.96% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -4466.3% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -1051.722% |
| Duearity AB (publ) | 10.58 Million SEK | -95.908% |
| Dignitana AB (publ) | 19.1 Million SEK | -8.517% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -298.673% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.743% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -151.296% |
| Iconovo AB (publ) | 7.72 Million SEK | -168.366% |
| Integrum AB (publ) | 6.42 Million SEK | -222.703% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -9962.42% |
| Mentice AB (publ) | 9.55 Million SEK | -116.92% |
| OssDsign AB (publ) | 3.15 Million SEK | -558.127% |
| Paxman AB (publ) | 13.57 Million SEK | -52.771% |
| Promimic AB (publ) | - SEK | -Infinity% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -205.002% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 34.784% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -381.444% |
| Senzime AB (publ) | 11.46 Million SEK | -80.773% |
| SpectraCure AB (publ) | 6.71 Million SEK | -208.635% |
| Stille AB | 62.94 Million SEK | 67.063% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.008% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 34.055% |